Comprehensive review of preclinical evaluation strategies for COVID-19 vaccine candidates: assessing immunogenicity, toxicology, and safety profiles
Abstract
Following the worldwide spread of Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), there is a vital requirement for safe and effective vaccines against Coronavirus disease 2019 (COVID-19). Therefore, several vaccine-candidate platforms have been designed, tested, and developed. Based on guidelines, preclinical studies are recommended to assess the safety and potency of COVID-19 vaccines in appropriate in vitro and in vivo settings. These studies provide essential information to describe the potential toxic properties of a vaccine and the formulation of vaccine agents during the preclinical trial phase. In toxicology studies, several factors must be considered, such as the appropriate animal species and strains, dosing timetable, mode of administration, time of sampling for biochemistry and antibody evaluation, and necropsy. Pharmacokinetic/ biodistribution studies are not usually required for infectious disease prophylaxis vaccines unless the vaccine contains a novel substance. Evaluating their biodistribution is crucial for newly developed vaccines, such as lipid nanoparticles –messenger RNA (LNP-mRNA), DNA, and Viral vectors in non-replicated (VVnr), or recombinant virus vaccines. The review highlights the importance of preclinical studies in assessing the safety and efficacy of vaccine candidates. This guidance is essential for researchers and manufacturers to design effective vaccines that can progress to clinical trials safely.
1. Zareie B, Roshani A, Mansournia MA, Rasouli MA, Moradi G. A model for COVID-19 prediction in Iran based on China parameters. Arch Iran Med 2020; 23: 244-248.
2. Yuen K-S, Ye Z-W, Fung S-Y, Chan C-P, Jin D-Y. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci 2020; 10: 40.
3. Wang M-Y, Zhao R, Gao L-J, Gao X-F, Wang D-P, Cao J-M. SARS-CoV-2: Structure, Biology, and Structure-Based therapeutics development. Front Cell Infect Microbiol 2020; 10: 587269.
4. Huang Y, Yang C, Xu X-F, Xu W, Liu S-W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 2020; 41: 1141-1149.
5. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease Inhibitor. Cell 2020; 181: 271-280.e8.
6. Jiang H-D, Tao Y-Y, Jia S-Y, Li J-X, Zhu F-C. Coronavirus disease 2019 vaccines: landscape of global studies and potential risks. Chin Med J (Engl) 2021; 134: 2037-2044.
7. Sjöberg P, Jones DR (2013). Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals: ICH M3 and M3(R2). pp. 299-309. https://link.springer.com/chapter/10.1007/978-1-4614-5950-7_14
8. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021; 21: 181-192.
9. FDA (2013). Guidance for industry M3(R2) Nonclinical Safety studies for the conduct of human clinical trials and marketing authorization for Pharmaceuticals. https://www.fda.gov/media/82725/download
10. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021; 21: 39-51.
11. Yadav PD, Ella R, Kumar S, Patil DR, Mohandas S, Shete AM, et al. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat Commun 2021; 12: 1386.
12. Elmancy L, Alkhatib H, Daou A. SARS-CoV-2: an analysis of the vaccine candidates tested in combatting and eliminating the COVID-19 virus. Vaccines (Basel) 2022; 10: 2086.
13. Valentin J-P, Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J Pharmacol Toxicol Methods 2008; 58: 77-87.
14. Green MD, Al-Humadi NH (2017). Preclinical toxicology of vaccines. In: A comprehensive guide to toxicology in nonclinical drug development. Elsevier; page 709-735.15. Kandeil A, Mostafa A, Hegazy RR, El-Shesheny R, El Taweel A,
Gomaa MR, et al. Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies. Vaccines (Basel) 2021; 9: 214.
16. Nomura Y, Noda K, Oohashi Y, Okuda S, Maki K, Ogawa T, et al. Proposal for the revision of the guidelines for Non-clinical studies of vaccines for the prevention of infectious diseases in Japan. Vaccine 2022; 40: 2810-2818.
17. Huang W, Percie du Sert N, Vollert J, Rice ASC. General Principles of Preclinical Study Design. Handb Exp Pharmacol 2020; 257: 55-69.
18. Jain S, Batra H, Yadav P, Chand S. COVID-19 vaccines currently under preclinical and clinical studies, and associated antiviral immune response. Vaccines (Basel) 2020; 8: 649.
19. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020; 369: 77-81.
20. Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 2021; 592: 283-289.
21. Conte C, Sogni F, Affanni P, Veronesi L, Argentiero A, Esposito S. Vaccines against coronaviruses: the state of the art. Vaccines (Basel) 2020; 8: 309.
22. Lima EJ da F, Almeida AM, de Ávila Kfouri. Vaccines for COVID-19-state of the art. Rev Bras Saúde Matern Infant 2021; 21(Suppl 1): S13-S19.
23. Ebenig A, Muraleedharan S, Kazmierski J, Todt D, Auste A, Anzaghe M, et al. In contrast to TH2-biased approaches, TH1 COVID-19 vaccines protect Syrian hamsters from severe disease without dexamethasone-treatable vaccine-associated enhanced respiratory pathology. bioRxiv 2021; 10.1101/2021.12.28.474359.
24. DiPiazza AT, Leist SR, Abiona OM, Moliva JI, Werner A, Minai M, et al. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity 2021; 54: 1869-1882.e6.
25. Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 2020; 369: 806-811.
26. Cavagnaro JA. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Rev Drug Discov 2002; 1: 469-475.
27. Abdoli A, Aalizadeh R, Aminianfar H, Kianmehr Z, Teimoori A, Azimi E, et al. Safety and potency of BIV1‐CovIran inactivated vaccine candidate for SARS‐CoV‐2: A preclinical study. Rev Med Virol 2022; 32(3): e2305.
28. Sunagar R, Prasad SD, Ella R, Vadrevu KM. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152). Front Immunol 2022; 13: 1063679.
29. Liu J, Budylowski P, Samson R, Griffin BD, Babuadze G, Rathod B, et al. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. Sci Adv 2022; 8(3): eabj9815.
30. van Doremalen N, Purushotham JN, Schulz JE, Holbrook MG, Bushmaker T, Carmody A, et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci Transl Med 2021; 13(607): eabh0755.
31. Pouriayevali MH, Teimoori A, Esmaeili S, Abdoli A, Doroud D, Salehi-Vaziri M, et al. Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein " [Vaccine 40(20) (2022) 2856-2868]. Vaccine 2022; 40: 7009.
32. Banihashemi SR, Es-Haghi A, Fallah Mehrabadi MH, Nofeli M, Mokarram AR, Ranjbar A, et al. Safety and efficacy of combined intramuscular/intranasal RAZI-COV PARS vaccine candidate against SARS-CoV-2: a preclinical study in several animal models. Front Immunol 2022; 13: 836745.
33. Eftekhari Z, Mousavi Nasab SD, Dorostkar R, Pourfathollah AA, Mamaghani MJ, Hassanzadeh SM, et al. Animal Pre-Clinical Study of an Inactivated SARS-CoV-2 Vaccine candidate (Osvid-19®): Immunogenicity, Protective, and Safety Aspects. J Popul Ther Clin Pharmacol 2023; 30: 111-130.
34. Corbett KS, Werner AP, Connell SO, Gagne M, Lai L, Moliva JI, et al. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nat Immunol 2021; 22: 1306-1315.
35. Tran TNM, May BP, Ung TT, Nguyen MK, Nguyen TTT, Dinh VL, et al. Preclinical immune response and safety evaluation of the protein subunit vaccine nanocovax for COVID-19. Front Immunol 2021; 12: 766112.
36. Kalnin KV, Plitnik T, Kishko M, Zhang J, Zhang D, Beauvais A, et al. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. NPJ Vaccines 2021; 6: 61.
37. Spencer AJ, Morris S, Ulaszewska M, Powers C, Kailath R, Bissett C, et al. The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B. 1.351) and other variants of concern in preclinical studies. EBioMedicine 2022; 77: 103902.
38. Li L, Honda-Okubo Y, Huang Y, Jang H, Carlock MA, Baldwin J, et al. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection. Vaccine 2021; 39: 5940-5953.
39. Dey A, Chozhavel Rajanathan TM, Chandra H, Pericherla HPR, Kumar S, Choonia HS, et al. Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models. Vaccine 2021; 39: 4108-4116.
40. Tscherne A, Schwarz JH, Rohde C, Kupke A, Kalodimou G, Limpinsel L, et al. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. Proc Natl Acad Sci U S A 2021; 118(28): e2026207118.
41. Pérez P, Albericio G, Astorgano D, Flores S, Sánchez-Corzo C, Sanchez-Cordon PJ, et al. Preclinical immune efficacy against SARS-CoV-2 beta B. 1.351 variant by MVA-based vaccine candidates. Front Immunol 2023; 14: 1264323.
42. Barreiro A, Prenafeta A, Bech-Sabat G, Roca M, Perozo Mur E, March R, et al. Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2. iScience 2023; 26: 106126.
43. Wu Y, Wu N, Jia X, Wu Y, Zhang X, Liu Y, et al. Long-term immune response to Omicron-specific mRNA vaccination in mice, hamsters, and nonhuman primates. MedComm (2020) 2023; 4(6): e460.
44. Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med 2021; 385: 239-250.
45. Bernadin O, Cochin M, Driouich JS, Laprie C, Steigler P, Boukes G, et al. Preclinical evaluation in hamster model of the mRNA COVID-19 vaccine candidate AfriVac 2121 (Wuhan) produced under the WHO/MPP mRNA Technology transfer programme. Vaccine 2024; 42: 126378.
46. Tan S, Zhao J, Hu X, Li Y, Wu Z, Lu G, et al. Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants. Sci Bull (Beijing) 2023; 68: 3192-3206.
47. van den Ouweland F, Charpentier N, Türeci Ö, Rizzi R, Mensa FJ, Lindemann C, et al. Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data. Hum Vaccin Immunother 2024; 20: 2315659.
48. McEwen A, Henson C. Quantitative whole-body autoradiography: past, present and future. Bioanalysis 2015; 7: 557-568.
49. Greaves P (2011). Histopathology of preclinical toxicity studies: interpretation and relevance in drug safety evaluation. Academic Press; 4th edition.
50. Gad SC (2008). Preclinical development handbook: toxicology. John Wiley & Sons. pp 1080.
51. Tonholo DR, Maltarollo VG, Kronenberger T, Silva IR, Azevedo PO, Oliveira RB, et al. Preclinical toxicity of innovative molecules: In vitro, in vivo and metabolism prediction. Chem Biol Interact 2020; 315: 108896.
52. Cavero I, Crumb W. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis. Expert Opin Drug Saf 2005; 4: 509-530.
53. Schalk JA, Mooi FR, Berbers GA, van Aerts LA, Ovelgönne H, Kimman TG. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin 2006; 2: 45-53.
54. Martins VT, Machado AS, Humbert MV, Christodoulides M, Coelho EAF. Preclinical assessment of the Immunogenicity of experimental leishmania vaccines. Methods Mol Biol 2022; 2410: 481-502.
55. Tan HX, Juno JA, Lee WS, Barber-Axthelm I, Kelly HG, Wragg KM, et al. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nat Commun 2021; 12: 1403.
56. Mukhopadhyay L, Yadav PD, Gupta N, Mohandas S, Patil DY, Shete-Aich A, et al. Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates. Indian J Med Res 2021; 153: 93-114.
57. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383: 2603-2615.
58. Forster R. Study designs for the nonclinical safety testing of new vaccine products. J Pharmacol Toxicol Methods 2012; 66: 1-7.
59. Sasaki E, Momose H, Hiradate Y, Furuhata K, Mizukami T, Hamaguchi I. Development of a preclinical humanized mouse model to evaluate acute toxicity of an influenza vaccine. Oncotarget 2018; 9: 25751-25763.
60. Ozdem SS. An overview of non-clinical safety studies in current Turkish regulations for the development of COVID-19 vaccines. Biologicals 2022; 75: 1-2.
61. Sifontes-Rodríguez S, Infante-Bourzac JF, Díaz-Rivero D, López-Feria Y, Pérez-Pérez M, Sosa-Roble E, et al. Repeated dose toxicity study of a live attenuated oral cholera vaccine in Sprague Dawley rats. Arch Med Res 2009; 40: 527-535.
62. CPMP. Note for Guidance on repeated dose Toxicity. CPMP/SWP/1042/99 corr. London EMEA 2001. https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-repeated-dose-toxicity_en.pdf
63. Adithan C. Principles of translational science in medicine: From bench to bedside, 2nd edition. Indian J Med Res 2017; 145: 408-409.
64. Bulgheroni A, Kinsner-Ovaskainen A, Hoffmann S, Hartung T, Prieto P. Estimation of acute oral toxicity using the No Observed Adverse Effect Level (NOAEL) from the 28 day repeated dose toxicity studies in rats. Regul Toxicol Pharmacol 2009; 53: 16-19.
65. Dubé C, Paris-Robidas S, Primakova I, Destexhe E, Ward BJ, Landry N, et al. Lack of effects on female fertility or pre-and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19. Reprod Toxicol 2022; 107: 69-80.
66. Bowman CJ, Bouressam M, Campion SN, Cappon GD, Catlin NR, Cutler MW, et al. Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine. Reprod Toxicol 2021; 103: 28-35.
67. Ramot Y, Caselli G, Aurisicchio L, Andreini I, Marra E, Luberto L, et al. Toxicity and Local Tolerance of COVID-e Vax, a Plasmid DNA vaccine for SARS-CoV-2, delivered by electroporation. Toxicol Pathol 2021; 49: 1255-1268.
68. Oliva-Hernández R, Fariñas-Medina M, Hernández-Salazar T, Oyarzabal-Vera A, Infante-Bourzac JF, Rodríguez-Salgueiro S, et al. Repeat-Dose and Local Tolerance Toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats. Toxicology 2022; 471: 153161.
69. Magdolenova Z, Collins A, Kumar A, Dhawan A, Stone V, Dusinska M. Mechanisms of genotoxicity. A review of in vitro and in vivo studies with engineered nanoparticles. Nanotoxicology 2014; 8: 233-278.
70. Reeve L, Baldrick P, Hewings S, Skinner M. A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy. J Appl Toxicol 2012; 32: 608-616.
71. Verschaeve L, Juutilainen J, Lagroye I, Miyakoshi J, Saunders R, de Seze R, et al. In vitro and in vivo genotoxicity of radiofrequency fields. Mutat Res 2010; 705: 252-268.
72. Baumstark-Khan C, Hellweg CE, Reitz G. Cytotoxicity and genotoxicity reporter systems based on the use of mammalian cells. Adv Biochem Eng Biotechnol 2010; 118: 113-151.
73. Jena GB, Kaul CL, Ramarao P. Regulatory requirements and ICH guidelines on carcinogenicity testing of pharmaceuticals: A review on current status. Indian J Pharmacol 2005; 37: 209-222.
74. Müller L, Kasper P, Schechtman L (2001). ICH guidances on genotoxicity and carcinogenicity: scientific background and regulatory practice.1st Edition. In: Genetic Toxicology and Cancer Risk Assessment. CRC Press. https://www.taylorfrancis.com/chapters/edit/10.1201/9780203904237-11/ich-guidances-genotoxicity-carcinogenicity-scientific-background-regulatory-practice-lutz-m%C3%BCller-peter-kasper-leonard-schechtman
75. Khalid K, Lim HX, Anwar A, Tan SH, Hwang JS, Ong SK, et al. Preclinical development of a novel Epitope-based DNA vaccine Candidate against SARS-CoV-2 and evaluation of immunogenicity in BALB/c Mice. AAPS PharmSciTech 2024; 25: 60.
2. Yuen K-S, Ye Z-W, Fung S-Y, Chan C-P, Jin D-Y. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci 2020; 10: 40.
3. Wang M-Y, Zhao R, Gao L-J, Gao X-F, Wang D-P, Cao J-M. SARS-CoV-2: Structure, Biology, and Structure-Based therapeutics development. Front Cell Infect Microbiol 2020; 10: 587269.
4. Huang Y, Yang C, Xu X-F, Xu W, Liu S-W. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 2020; 41: 1141-1149.
5. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease Inhibitor. Cell 2020; 181: 271-280.e8.
6. Jiang H-D, Tao Y-Y, Jia S-Y, Li J-X, Zhu F-C. Coronavirus disease 2019 vaccines: landscape of global studies and potential risks. Chin Med J (Engl) 2021; 134: 2037-2044.
7. Sjöberg P, Jones DR (2013). Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals: ICH M3 and M3(R2). pp. 299-309. https://link.springer.com/chapter/10.1007/978-1-4614-5950-7_14
8. Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021; 21: 181-192.
9. FDA (2013). Guidance for industry M3(R2) Nonclinical Safety studies for the conduct of human clinical trials and marketing authorization for Pharmaceuticals. https://www.fda.gov/media/82725/download
10. Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2021; 21: 39-51.
11. Yadav PD, Ella R, Kumar S, Patil DR, Mohandas S, Shete AM, et al. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat Commun 2021; 12: 1386.
12. Elmancy L, Alkhatib H, Daou A. SARS-CoV-2: an analysis of the vaccine candidates tested in combatting and eliminating the COVID-19 virus. Vaccines (Basel) 2022; 10: 2086.
13. Valentin J-P, Hammond T. Safety and secondary pharmacology: successes, threats, challenges and opportunities. J Pharmacol Toxicol Methods 2008; 58: 77-87.
14. Green MD, Al-Humadi NH (2017). Preclinical toxicology of vaccines. In: A comprehensive guide to toxicology in nonclinical drug development. Elsevier; page 709-735.15. Kandeil A, Mostafa A, Hegazy RR, El-Shesheny R, El Taweel A,
Gomaa MR, et al. Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies. Vaccines (Basel) 2021; 9: 214.
16. Nomura Y, Noda K, Oohashi Y, Okuda S, Maki K, Ogawa T, et al. Proposal for the revision of the guidelines for Non-clinical studies of vaccines for the prevention of infectious diseases in Japan. Vaccine 2022; 40: 2810-2818.
17. Huang W, Percie du Sert N, Vollert J, Rice ASC. General Principles of Preclinical Study Design. Handb Exp Pharmacol 2020; 257: 55-69.
18. Jain S, Batra H, Yadav P, Chand S. COVID-19 vaccines currently under preclinical and clinical studies, and associated antiviral immune response. Vaccines (Basel) 2020; 8: 649.
19. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020; 369: 77-81.
20. Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 2021; 592: 283-289.
21. Conte C, Sogni F, Affanni P, Veronesi L, Argentiero A, Esposito S. Vaccines against coronaviruses: the state of the art. Vaccines (Basel) 2020; 8: 309.
22. Lima EJ da F, Almeida AM, de Ávila Kfouri. Vaccines for COVID-19-state of the art. Rev Bras Saúde Matern Infant 2021; 21(Suppl 1): S13-S19.
23. Ebenig A, Muraleedharan S, Kazmierski J, Todt D, Auste A, Anzaghe M, et al. In contrast to TH2-biased approaches, TH1 COVID-19 vaccines protect Syrian hamsters from severe disease without dexamethasone-treatable vaccine-associated enhanced respiratory pathology. bioRxiv 2021; 10.1101/2021.12.28.474359.
24. DiPiazza AT, Leist SR, Abiona OM, Moliva JI, Werner A, Minai M, et al. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity 2021; 54: 1869-1882.e6.
25. Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 2020; 369: 806-811.
26. Cavagnaro JA. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat Rev Drug Discov 2002; 1: 469-475.
27. Abdoli A, Aalizadeh R, Aminianfar H, Kianmehr Z, Teimoori A, Azimi E, et al. Safety and potency of BIV1‐CovIran inactivated vaccine candidate for SARS‐CoV‐2: A preclinical study. Rev Med Virol 2022; 32(3): e2305.
28. Sunagar R, Prasad SD, Ella R, Vadrevu KM. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152). Front Immunol 2022; 13: 1063679.
29. Liu J, Budylowski P, Samson R, Griffin BD, Babuadze G, Rathod B, et al. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. Sci Adv 2022; 8(3): eabj9815.
30. van Doremalen N, Purushotham JN, Schulz JE, Holbrook MG, Bushmaker T, Carmody A, et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. Sci Transl Med 2021; 13(607): eabh0755.
31. Pouriayevali MH, Teimoori A, Esmaeili S, Abdoli A, Doroud D, Salehi-Vaziri M, et al. Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein " [Vaccine 40(20) (2022) 2856-2868]. Vaccine 2022; 40: 7009.
32. Banihashemi SR, Es-Haghi A, Fallah Mehrabadi MH, Nofeli M, Mokarram AR, Ranjbar A, et al. Safety and efficacy of combined intramuscular/intranasal RAZI-COV PARS vaccine candidate against SARS-CoV-2: a preclinical study in several animal models. Front Immunol 2022; 13: 836745.
33. Eftekhari Z, Mousavi Nasab SD, Dorostkar R, Pourfathollah AA, Mamaghani MJ, Hassanzadeh SM, et al. Animal Pre-Clinical Study of an Inactivated SARS-CoV-2 Vaccine candidate (Osvid-19®): Immunogenicity, Protective, and Safety Aspects. J Popul Ther Clin Pharmacol 2023; 30: 111-130.
34. Corbett KS, Werner AP, Connell SO, Gagne M, Lai L, Moliva JI, et al. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nat Immunol 2021; 22: 1306-1315.
35. Tran TNM, May BP, Ung TT, Nguyen MK, Nguyen TTT, Dinh VL, et al. Preclinical immune response and safety evaluation of the protein subunit vaccine nanocovax for COVID-19. Front Immunol 2021; 12: 766112.
36. Kalnin KV, Plitnik T, Kishko M, Zhang J, Zhang D, Beauvais A, et al. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. NPJ Vaccines 2021; 6: 61.
37. Spencer AJ, Morris S, Ulaszewska M, Powers C, Kailath R, Bissett C, et al. The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B. 1.351) and other variants of concern in preclinical studies. EBioMedicine 2022; 77: 103902.
38. Li L, Honda-Okubo Y, Huang Y, Jang H, Carlock MA, Baldwin J, et al. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection. Vaccine 2021; 39: 5940-5953.
39. Dey A, Chozhavel Rajanathan TM, Chandra H, Pericherla HPR, Kumar S, Choonia HS, et al. Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models. Vaccine 2021; 39: 4108-4116.
40. Tscherne A, Schwarz JH, Rohde C, Kupke A, Kalodimou G, Limpinsel L, et al. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. Proc Natl Acad Sci U S A 2021; 118(28): e2026207118.
41. Pérez P, Albericio G, Astorgano D, Flores S, Sánchez-Corzo C, Sanchez-Cordon PJ, et al. Preclinical immune efficacy against SARS-CoV-2 beta B. 1.351 variant by MVA-based vaccine candidates. Front Immunol 2023; 14: 1264323.
42. Barreiro A, Prenafeta A, Bech-Sabat G, Roca M, Perozo Mur E, March R, et al. Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2. iScience 2023; 26: 106126.
43. Wu Y, Wu N, Jia X, Wu Y, Zhang X, Liu Y, et al. Long-term immune response to Omicron-specific mRNA vaccination in mice, hamsters, and nonhuman primates. MedComm (2020) 2023; 4(6): e460.
44. Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med 2021; 385: 239-250.
45. Bernadin O, Cochin M, Driouich JS, Laprie C, Steigler P, Boukes G, et al. Preclinical evaluation in hamster model of the mRNA COVID-19 vaccine candidate AfriVac 2121 (Wuhan) produced under the WHO/MPP mRNA Technology transfer programme. Vaccine 2024; 42: 126378.
46. Tan S, Zhao J, Hu X, Li Y, Wu Z, Lu G, et al. Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants. Sci Bull (Beijing) 2023; 68: 3192-3206.
47. van den Ouweland F, Charpentier N, Türeci Ö, Rizzi R, Mensa FJ, Lindemann C, et al. Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data. Hum Vaccin Immunother 2024; 20: 2315659.
48. McEwen A, Henson C. Quantitative whole-body autoradiography: past, present and future. Bioanalysis 2015; 7: 557-568.
49. Greaves P (2011). Histopathology of preclinical toxicity studies: interpretation and relevance in drug safety evaluation. Academic Press; 4th edition.
50. Gad SC (2008). Preclinical development handbook: toxicology. John Wiley & Sons. pp 1080.
51. Tonholo DR, Maltarollo VG, Kronenberger T, Silva IR, Azevedo PO, Oliveira RB, et al. Preclinical toxicity of innovative molecules: In vitro, in vivo and metabolism prediction. Chem Biol Interact 2020; 315: 108896.
52. Cavero I, Crumb W. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis. Expert Opin Drug Saf 2005; 4: 509-530.
53. Schalk JA, Mooi FR, Berbers GA, van Aerts LA, Ovelgönne H, Kimman TG. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin 2006; 2: 45-53.
54. Martins VT, Machado AS, Humbert MV, Christodoulides M, Coelho EAF. Preclinical assessment of the Immunogenicity of experimental leishmania vaccines. Methods Mol Biol 2022; 2410: 481-502.
55. Tan HX, Juno JA, Lee WS, Barber-Axthelm I, Kelly HG, Wragg KM, et al. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nat Commun 2021; 12: 1403.
56. Mukhopadhyay L, Yadav PD, Gupta N, Mohandas S, Patil DY, Shete-Aich A, et al. Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates. Indian J Med Res 2021; 153: 93-114.
57. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383: 2603-2615.
58. Forster R. Study designs for the nonclinical safety testing of new vaccine products. J Pharmacol Toxicol Methods 2012; 66: 1-7.
59. Sasaki E, Momose H, Hiradate Y, Furuhata K, Mizukami T, Hamaguchi I. Development of a preclinical humanized mouse model to evaluate acute toxicity of an influenza vaccine. Oncotarget 2018; 9: 25751-25763.
60. Ozdem SS. An overview of non-clinical safety studies in current Turkish regulations for the development of COVID-19 vaccines. Biologicals 2022; 75: 1-2.
61. Sifontes-Rodríguez S, Infante-Bourzac JF, Díaz-Rivero D, López-Feria Y, Pérez-Pérez M, Sosa-Roble E, et al. Repeated dose toxicity study of a live attenuated oral cholera vaccine in Sprague Dawley rats. Arch Med Res 2009; 40: 527-535.
62. CPMP. Note for Guidance on repeated dose Toxicity. CPMP/SWP/1042/99 corr. London EMEA 2001. https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-repeated-dose-toxicity_en.pdf
63. Adithan C. Principles of translational science in medicine: From bench to bedside, 2nd edition. Indian J Med Res 2017; 145: 408-409.
64. Bulgheroni A, Kinsner-Ovaskainen A, Hoffmann S, Hartung T, Prieto P. Estimation of acute oral toxicity using the No Observed Adverse Effect Level (NOAEL) from the 28 day repeated dose toxicity studies in rats. Regul Toxicol Pharmacol 2009; 53: 16-19.
65. Dubé C, Paris-Robidas S, Primakova I, Destexhe E, Ward BJ, Landry N, et al. Lack of effects on female fertility or pre-and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19. Reprod Toxicol 2022; 107: 69-80.
66. Bowman CJ, Bouressam M, Campion SN, Cappon GD, Catlin NR, Cutler MW, et al. Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine. Reprod Toxicol 2021; 103: 28-35.
67. Ramot Y, Caselli G, Aurisicchio L, Andreini I, Marra E, Luberto L, et al. Toxicity and Local Tolerance of COVID-e Vax, a Plasmid DNA vaccine for SARS-CoV-2, delivered by electroporation. Toxicol Pathol 2021; 49: 1255-1268.
68. Oliva-Hernández R, Fariñas-Medina M, Hernández-Salazar T, Oyarzabal-Vera A, Infante-Bourzac JF, Rodríguez-Salgueiro S, et al. Repeat-Dose and Local Tolerance Toxicity of SARS-CoV-2 FINLAY-FR-02 vaccine candidate in Sprague Dawley rats. Toxicology 2022; 471: 153161.
69. Magdolenova Z, Collins A, Kumar A, Dhawan A, Stone V, Dusinska M. Mechanisms of genotoxicity. A review of in vitro and in vivo studies with engineered nanoparticles. Nanotoxicology 2014; 8: 233-278.
70. Reeve L, Baldrick P, Hewings S, Skinner M. A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy. J Appl Toxicol 2012; 32: 608-616.
71. Verschaeve L, Juutilainen J, Lagroye I, Miyakoshi J, Saunders R, de Seze R, et al. In vitro and in vivo genotoxicity of radiofrequency fields. Mutat Res 2010; 705: 252-268.
72. Baumstark-Khan C, Hellweg CE, Reitz G. Cytotoxicity and genotoxicity reporter systems based on the use of mammalian cells. Adv Biochem Eng Biotechnol 2010; 118: 113-151.
73. Jena GB, Kaul CL, Ramarao P. Regulatory requirements and ICH guidelines on carcinogenicity testing of pharmaceuticals: A review on current status. Indian J Pharmacol 2005; 37: 209-222.
74. Müller L, Kasper P, Schechtman L (2001). ICH guidances on genotoxicity and carcinogenicity: scientific background and regulatory practice.1st Edition. In: Genetic Toxicology and Cancer Risk Assessment. CRC Press. https://www.taylorfrancis.com/chapters/edit/10.1201/9780203904237-11/ich-guidances-genotoxicity-carcinogenicity-scientific-background-regulatory-practice-lutz-m%C3%BCller-peter-kasper-leonard-schechtman
75. Khalid K, Lim HX, Anwar A, Tan SH, Hwang JS, Ong SK, et al. Preclinical development of a novel Epitope-based DNA vaccine Candidate against SARS-CoV-2 and evaluation of immunogenicity in BALB/c Mice. AAPS PharmSciTech 2024; 25: 60.
| Files | ||
| Issue | Vol 17 No 1 (2025) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/ijm.v17i1.17796 | |
| Keywords | ||
| Animals; COVID-19 vaccines; Immunogenicity; Toxicity tests | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Doroud D, Daneshi M, Kazemi-Lomedash F, Eftekhari Z. Comprehensive review of preclinical evaluation strategies for COVID-19 vaccine candidates: assessing immunogenicity, toxicology, and safety profiles. Iran J Microbiol. 2025;17(1):1-18.
